Affordable Access

deepdyve-link
Publisher Website

Atopic dermatitis is not associated with SARS-CoV-2 outcomes

Authors
  • Rakita, Uros1
  • Kaundinya, Trisha2
  • Guraya, Armaan3
  • Nelson, Kamaria4
  • Maner, Brittany5
  • Manjunath, Jaya4
  • Schwartzman, Gabrielle4
  • Lane, Brittany6
  • Silverberg, Jonathan I.4, 7
  • 1 Rosalind Franklin University,
  • 2 Northwestern Feinberg School of Medicine,
  • 3 Midwestern University Chicago College of Osteopathic Medicine,
  • 4 George Washington School of Medicine,
  • 5 Ross University School of Medicine,
  • 6 Michigan State University College of Human Medicine,
  • 7 George Washington University School of Medicine and Health Sciences,
Type
Published Article
Journal
Archives of Dermatological Research
Publisher
Springer-Verlag
Publication Date
Sep 17, 2021
Pages
1–4
Identifiers
DOI: 10.1007/s00403-021-02276-1
PMID: 34533589
PMCID: PMC8447890
Source
PubMed Central
Keywords
Disciplines
  • Concise Communications
License
Unknown

Abstract

Atopic dermatitis is characterized by immune dysregulation, which may predispose toward worse COVID-19 outcomes. We conducted a retrospective cohort study to investigate the relationship of atopic dermatitis with COVID-19 symptom severity, hospitalization, length of hospital stay, requirement for oxygen therapy, long-term morbidity and mortality. Multivariable logistic regression models were constructed to examine the impact of atopic dermatitis (independent variable) on COVID-19 symptom severity, hospitalization, length of hospital stay, requirement for oxygen therapy, long-term morbidity and mortality (dependent variables). SARS-CoV-2 positive adult patients with diagnosed AD had similar odds of hospitalization (adjusted odds ratio [95% confidence interval]: 0.51 [0.20–1.35]), acute level of care at initial medical care (0.67 [0.35–1.30]), severe-critical SARS-CoV-2 (0.82 [0.29–2.30]), requirement of supplemental non-mechanical oxygen therapy (1.33 [0.50–3.58]), extended hospital stay (2.24 [0.36–13.85]), lingering COVID-19 symptoms (0.58 [0.06–5.31]) and COVID-19 death (0.002 [< 0.001– > 999]) compared to patients without AD. Our findings suggest AD is not an independent risk factor for COVID-19 severity or complications.

Report this publication

Statistics

Seen <100 times